005690.KQ Pharmicell Co., Ltd. (파미셀) Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
03:19
Apr 29
Apr 29
Parami Cell cheap CCL play
Parami Cell is a cheaper CCL and PCB materials play: 2026 operating profit could exceed 55 billion won, PER around 20x versus domestic PCB 27x and Taiwan CCL 43x; watch with Doosan earnings.
MED
02:21
Apr 29
Apr 29
Pamishel cheap CCL earnings play.
Pamishel is a CCL/PCB materials name with expected 2025 operating profit of 55 billion won and a 20x PER, cheap versus domestic PCB peers at 27x, Taiwanese CCL peers at 43x, and global materials peers at 34x. If Doosan's upcoming earnings are good, Pamishel should be bought.
MED
04:12
Apr 28
Apr 28
Pharmicell exclusively supplies Doosan CCL materials.
Pharmicell is not just a biotech company; it exclusively supplies low-dielectric resin and curing agents to Doosan's CCL business. About 60-70% of revenue comes from Doosan, operating margin is above 30%, and a third plant should double capacity by next year as Doosan expands.
MED
00:25
Apr 21
Apr 21
Watch Doosan and Pharmicell materials
Doosan's technology investment expectations and Pharmicell's CCL and copper foil laminate materials exposure make both worth watching.
MED
00:19
Apr 16
Apr 16
Pharmicell moves with Doosan capex.
Pharmicell can move with Doosan because it supplies resin used in CCL; Doosan's capex expansion adds momentum.
LOW
About 005690.KQ Investor Commentary
Across the available history and selected sources, Buzzberg tracks 005690.KQ (Pharmicell Co., Ltd. (파미셀)) across 2 sources: 4 bullish vs 0 bearish calls from 5 authors. Historical directional balance: 80% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 5 total trade ideas tracked. Latest voices: Park Jin, Park Ji-hoon, Oh Tae-woo.